Zepbound vs Ozempic: Real-World Evidence Comparison

What Are Zepbound and Ozempic, and How Do They Differ?

Zepbound and Ozempic belong to the same drug class but work through different receptor pathways. Zepbound (tirzepatide) activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. Ozempic (semaglutide) targets only the GLP-1 receptor. That single mechanistic difference appears to translate into measurably larger weight and glycemic reductions with tirzepatide across multiple trial populations.

Mechanism: GIP/GLP-1 Dual Agonism vs. GLP-1 Alone

The GLP-1 receptor drives appetite suppression, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. Adding GIP agonism appears to amplify these effects by acting on adipose tissue and central reward circuits involved in food intake. Preclinical data suggest GIP co-stimulation reduces nausea relative to pure GLP-1 agonism at equivalent weight-loss doses, though head-to-head tolerability comparisons in humans are still accumulating. See the receptor pharmacology overview on PubMed.

FDA Approval Status

Zepbound received FDA approval in November 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. FDA prescribing information is available here.

Ozempic (semaglutide 0.5 mg, 1.0 mg, 2.0 mg) carries FDA approval only for type 2 diabetes and cardiovascular risk reduction in adults with established cardiovascular disease. Prescribing Ozempic for weight loss alone is considered off-label use. Wegovy, a higher-dose formulation of the same semaglutide molecule at 2.4 mg, is the on-label obesity agent.

This regulatory distinction matters for insurance coverage. Patients who receive Ozempic for weight loss without a diabetes diagnosis may face claim denials that would not apply to Zepbound.

Clinical Trial Weight-Loss Data: SURMOUNT-1 vs. STEP-1

The two landmark phase 3 trials offer the clearest side-by-side picture of what each drug does in people with obesity but without type 2 diabetes.

SURMOUNT-1 (Tirzepatide)

SURMOUNT-1 enrolled 2,539 adults with a BMI ≥30 (or ≥27 with at least one comorbidity) and no type 2 diabetes. Participants received tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks. The full results were published in the New England Journal of Medicine in 2022.

At 72 weeks:

• Tirzepatide 15 mg produced a mean weight reduction of 20.9% from baseline.
• Tirzepatide 10 mg produced 19.5% mean weight reduction.
• Tirzepatide 5 mg produced 15.0% mean weight reduction.
• Placebo produced 3.1% mean weight reduction.

All active doses achieved P<0.001 vs. Placebo for both weight loss and the proportion of patients losing ≥5% of body weight.

STEP-1 (Semaglutide 2.4 mg)

STEP-1 enrolled 1,961 adults with obesity or overweight with comorbidities and no type 2 diabetes. Semaglutide 2.4 mg weekly (Wegovy formulation) or placebo was given for 68 weeks. Published in the New England Journal of Medicine in 2021.

At 68 weeks:

• Semaglutide 2.4 mg produced a mean weight reduction of 14.9% from baseline.
• Placebo produced 2.4% mean weight reduction.
• 86.4% of semaglutide participants lost ≥5% of body weight vs. 31.5% on placebo (P<0.001).

The 6-percentage-point gap in mean weight loss between the best tirzepatide arm and semaglutide 2.4 mg represents a clinically meaningful difference, though the trials were not designed for direct comparison and enrolled different populations across different timeframes.

Head-to-Head Evidence: SURPASS-CVOT and SUSTAIN-7

SUSTAIN-7: Semaglutide vs. Dulaglutide in Diabetes

SUSTAIN-7 was not a tirzepatide trial, but it established semaglutide's superiority over another GLP-1 agonist (dulaglutide) in glycemic and weight outcomes in 1,201 patients with type 2 diabetes. Published in The Lancet Diabetes and Endocrinology and indexed on PubMed. At 40 weeks, semaglutide 1.0 mg reduced HbA1c by 1.5 percentage points and body weight by 6.5 kg, outperforming dulaglutide 1.5 mg on both endpoints. This trial helps contextualize how semaglutide performs within the GLP-1 class before comparing it to the dual-agonist tirzepatide.

SURPASS-2: Tirzepatide vs. Semaglutide 1.0 mg in Type 2 Diabetes

SURPASS-2 is the closest available head-to-head trial. It randomized 1,879 patients with type 2 diabetes to tirzepatide 5 mg, 10 mg, or 15 mg weekly vs. Semaglutide 1.0 mg weekly for 40 weeks. Full results are on PubMed.

Results for HbA1c reduction:

• Tirzepatide 5 mg: -2.01 percentage points
• Tirzepatide 10 mg: -2.24 percentage points
• Tirzepatide 15 mg: -2.30 percentage points
• Semaglutide 1.0 mg: -1.86 percentage points

Weight loss at 40 weeks:

• Tirzepatide 15 mg: -11.2 kg
• Semaglutide 1.0 mg: -5.7 kg

All tirzepatide doses were superior to semaglutide 1.0 mg for both HbA1c reduction and body weight (P<0.001 for each comparison). The comparator dose (semaglutide 1.0 mg) was not the maximum approved dose, which limits direct interpretation for the obesity setting, but the magnitude of separation was consistent across secondary endpoints.

Real-World Evidence: What Happens Outside Clinical Trials?

Pharmacy Claims and Retrospective Cohort Data

Real-world data through 2024 generally confirm the trial hierarchy. A retrospective analysis published in JAMA Internal Medicine in 2024 examined pharmacy claims and electronic health records from 41,222 adults with type 2 diabetes or obesity prescribed tirzepatide or semaglutide. See the JAMA Internal Medicine publication here.

At 12 months of follow-up:

• Mean weight loss was 15.3% with tirzepatide vs. 8.3% with semaglutide (adjusted difference: -6.9 percentage points, 95% CI -7.1 to -6.7, P<0.001).
• Tirzepatide users were more likely to achieve ≥10% weight loss (60.1% vs. 32.4%) and ≥15% weight loss (39.0% vs. 15.7%).
• Discontinuation rates at 12 months were similar: 45.7% for tirzepatide vs. 53.2% for semaglutide.

The discontinuation rates in this real-world sample are notably higher than trial dropout rates, reflecting cost barriers, supply shortages, and side-effect intolerance that get filtered out of randomized controlled trials.

Tolerability in Real-World Practice

Both drugs share a gastrointestinal side-effect profile. The most commonly reported adverse events in trials and post-marketing surveillance are nausea, vomiting, diarrhea, and constipation, typically most pronounced during dose escalation. The FDA's adverse-event reporting database provides ongoing post-marketing data.

In SURMOUNT-1, 4.3% of tirzepatide 15 mg recipients discontinued due to gastrointestinal events vs. 2.6% with placebo. In STEP-1, 4.5% of semaglutide 2.4 mg recipients discontinued for the same reason.

Clinician reports from weight-management practices suggest that patients switching from semaglutide to tirzepatide sometimes experience a second wave of nausea during initial dose titration on tirzepatide, even if they tolerated semaglutide well. This occurs because the GIP receptor adds a new agonist interaction that the gut must adapt to separately.

Cardiovascular Outcomes: Semaglutide Has the Stronger Dataset Today

The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% vs. Placebo over a median follow-up of 39.8 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). Published in the New England Journal of Medicine in 2023.

Tirzepatide's dedicated cardiovascular outcomes trial, SURMOUNT-MMO, is ongoing, with results expected in the mid-2020s. Clinicians advising patients with established ASCVD who need both weight loss and proven cardiovascular risk reduction may currently favor the semaglutide molecule (Wegovy) on the strength of SELECT while SURMOUNT-MMO matures.

Glycemic Control: Which Drug Performs Better for Type 2 Diabetes?

HbA1c Reduction

For patients with type 2 diabetes, tirzepatide shows larger absolute HbA1c reductions across all completed SURPASS trials. In SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.30 percentage points vs. 1.86 percentage points with semaglutide 1.0 mg. In SURPASS-1 (vs. Placebo), up to 40% of tirzepatide 15 mg recipients reached an HbA1c below 5.7%, the normal glycemic range, by week 40. SURPASS-1 is indexed on PubMed.

The American Diabetes Association's 2024 Standards of Care state that for patients with type 2 diabetes who need weight loss as a treatment goal, GLP-1 receptor agonists with the greatest weight-loss efficacy should be prioritized, which positions tirzepatide favorably. ADA 2024 Standards of Care are available via Diabetes Care.

Fasting Glucose and Post-Prandial Control

The dual GIP/GLP-1 mechanism may confer a modest additional advantage in post-prandial glucose management, because GIP receptor activation enhances insulin secretion through a pathway partially independent of GLP-1. In practice, clinicians measure outcomes at 12-week HbA1c checks rather than relying on mechanistic predictions alone.

Cost, Coverage, and Access: A Practical Comparison

Drug cost without insurance is similar for both agents, typically $900 to $1,000 per month for the branded pens. However, coverage field differs.

• Ozempic is covered by most commercial and Medicare Part D plans when prescribed for type 2 diabetes.
• Zepbound has faced variable formulary placement since its 2023 launch. Eli Lilly's savings card can reduce cost to as low as $550 per month for eligible commercially insured patients as of early 2025.
• Neither Ozempic (for weight loss) nor Zepbound is reliably covered under standard Medicare Part D for obesity without diabetes due to the ongoing exclusion of weight-loss drugs from Medicare drug benefit tiers, though the Treat and Reduce Obesity Act remains under legislative consideration.

Supply shortages affected semaglutide (Ozempic and Wegovy) heavily in 2022 and 2023, and tirzepatide (Mounjaro and Zepbound) through 2024. As of early 2025, both manufacturers report improved supply, but regional pharmacy stock can vary week to week. The FDA maintains an up-to-date drug shortage database.

Switching from Zepbound to Ozempic (or Vice Versa)

Should You Switch?

Switching is appropriate in specific clinical situations: insurance-driven formulary changes, intolerable side effects on one agent, inadequate glycemic response, or a new cardiovascular indication that favors semaglutide. Switching is generally not recommended simply because a patient sees better results reported online.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines note that if a patient achieves less than 5% weight loss after 12 to 16 weeks at the maximum tolerated dose of a GLP-1 or dual-agonist agent, switching drug class or formulation is a reasonable clinical decision. AACE obesity guidelines are available at AACE.

How to Switch: No Mandatory Washout

No regulatory guidance mandates a washout period when transitioning between GLP-1 receptor agonists or between a GLP-1 agonist and a dual GIP/GLP-1 agonist. Both agents have elimination half-lives of approximately one week. In practice, most clinicians follow one of two protocols:

1. Same-day switch: Stop the current agent; begin the new agent at its lowest starting dose (tirzepatide 2.5 mg or semaglutide 0.25 mg) the following injection day. This avoids any gap in appetite suppression but requires restarting the slow titration schedule.
2. One-week gap: Allow a single missed injection before beginning the new agent. This approach reduces the theoretical risk of overlapping gastrointestinal side effects.

Clinicians in HealthRX practice data consistently prefer the same-day switch at the starting dose, citing lower patient dropout during the transition period compared to patients who take a prolonged gap and lose appetite-suppression momentum.

Switching from Ozempic to Zepbound

Patients moving from Ozempic to Zepbound should anticipate:

• A renewed titration period of 4 to 20 weeks to reach maximum tirzepatide dose (15 mg).
• Possible temporary weight plateau or minor regain during the lower-dose titration phase before tirzepatide reaches therapeutic dose.
• A possible second nausea period, especially in patients who had GI adaptation to semaglutide but not yet to GIP agonism.

Switching from Zepbound to Ozempic

Patients moving from Zepbound to Ozempic should anticipate:

• Lower average weight loss ceiling based on available trial data.
• Potentially better cardiovascular outcomes data if they carry established ASCVD, given SELECT trial results for semaglutide.
• Formulary approval may be faster for semaglutide if the patient has a type 2 diabetes diagnosis on file.

Side-Effect Profile: A Direct Comparison

| Side Effect | Tirzepatide (SURMOUNT-1) | Semaglutide (STEP-1) | |---|---|---| | Nausea | 30.5% (15 mg group) | 44.2% (2.4 mg group) | | Diarrhea | 22.4% | 29.7% | | Vomiting | 9.5% | 24.8% | | Constipation | 17.8% | 24.4% | | Discontinuation (GI) | 4.3% | 4.5% |

Across SURMOUNT-1, semaglutide's comparator arm was not included, so these figures come from separate trials in different populations and should not be interpreted as a controlled comparison. The lower nausea rate with tirzepatide in SURMOUNT-1 relative to STEP-1 semaglutide may partly reflect differences in the starting dose, titration schedule, and population characteristics rather than a true tolerability advantage.

Both drugs carry FDA boxed warnings for thyroid C-cell tumors based on rodent data, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. The full tirzepatide prescribing information is here.

Who Should Choose Which Drug?

Zepbound Is Likely the Better Choice If You:

• Have obesity without type 2 diabetes and need maximum weight-loss efficacy.
• Have type 2 diabetes and need the largest possible HbA1c reduction.
• Have tried semaglutide at therapeutic dose for at least 12 weeks and lost less than 5% body weight.
• Have commercial insurance that covers Zepbound and can access the manufacturer savings program.

Ozempic (or Wegovy) Is Likely the Better Choice If You:

• Have established atherosclerotic cardiovascular disease and need a proven MACE-reduction agent (semaglutide SELECT data apply; tirzepatide cardiovascular data are pending).
• Have type 2 diabetes and your insurer covers Ozempic but not Zepbound.
• Previously tolerated semaglutide and achieved clinically meaningful weight loss (≥10%) and want to remain on a proven agent.
• Need the long-term cardiovascular safety data that semaglutide has accumulated across LEADER, SUSTAIN-6, and SELECT.

The Endocrine Society's 2022 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should consider the magnitude of weight loss, the presence of comorbidities, patient preferences, and drug cost and access when selecting among available anti-obesity medications." Full guideline text is available through the Journal of Clinical Endocrinology and Metabolism.

Long-Term Weight Maintenance: What Real-World Data Show

Both drugs require continued use to maintain weight loss. The SURMOUNT-4 extension trial showed that patients who stopped tirzepatide after 36 weeks regained approximately two-thirds of lost weight within 52 weeks. SURMOUNT-4 is indexed on PubMed.

The STEP-4 withdrawal trial for semaglutide showed similar regain patterns: participants who switched to placebo after 20 weeks of semaglutide regained approximately two-thirds of lost weight over the next 48 weeks. STEP-4 is available on PubMed.

These findings confirm that both tirzepatide and semaglutide treat obesity as a chronic condition. Stopping either drug without a transition to another weight-management intervention is associated with clinically significant weight regain regardless of which agent was used.